Cleveland, August 29, 2025 — Leads & Copy — Abeona Therapeutics Inc. (Nasdaq: ABEO) announced its management team will participate in investor conferences in September 2025, including a fireside chat at the Cantor Global Healthcare Conference on September 4 at 10:20 a.m. ET and a company presentation at the H.C. Wainwright 27th Annual Global Investment Conference on September 9 at 2:00 p.m. ET.
Live webcasts and replays will be available in the Investors section of the Abeona website under “Events”.
Abeona Therapeutics is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Its product, ZEVASKYN™ (prademagene zamikeracel), treats wounds in recessive dystrophic epidermolysis bullosa (RDEB) patients. Abeona’s facility in Cleveland manufactures ZEVASKYN, and the company is also developing AAV-based gene therapies for ophthalmic diseases and next-generation AAV capsids.
Investor and Media Contact: Greg Gin, VP, Investor Relations and Corporate Communications, ir@abeonatherapeutics.com
Source: Abeona Therapeutics Inc.
